Dognosis

Breathe Easy analyzes breath profiles to help doctors evaluate cancer risk without needles or scans.

The page invites participation in FirstAlert and SANKET, CTRI-registered clinical studies testing Breathe Easy for cancer risk assessment.

Dognosis combines canine olfaction and breath VOC analysis to assess cancer risk, validated in a peer-reviewed *Journal of Clinical Oncology* Phase II study.

How dogs came to detect disease, from a 1989 case in The Lancet to today, and why medicine hasn't adopted them yet.

The page shares updates on canine cancer detection research, clinical trials, team stories, and answers to cancer-related questions.

Two founders, two very different paths, and one idea: dogs can do something for medicine that nothing else can.

This quarter was when Dognosis gave a long howl, and the world howled back.

A breath test using trained dogs detects seven major cancers with over 90% accuracy, including early-stage disease, according to a *Journal of Clinical Oncology* study (Kulgod et al., 2026).

Dognosis, a deep-tech company scaling canine olfactory intelligence for healthcare, joins Accel Atoms X, a LeapTech program supported by Accel India and Prosus.

Dognosis has been selected for Nasscom's Emerge 50, Class of 2026, in the Healthtech and Biosciences track. Winners were felicitated in person at Nasscom Future Forge on 6th and 7th August in Bangalore, the flagship gathering for India's deeptech ecosystem.

Dognosis is named to YourStory’s Tech30 2026, an annual list of early-stage startups shaping India’s technology future, announced at TechSparks 2026.

The page invites applicants to join the team developing Breathe Easy, a breath VOC analysis tool for cancer risk assessment.

The page introduces the team and advisors behind the Breathe Easy project, including scientists, clinicians, engineers, and canine handlers.

A Bangalore-based biotech company develops Breathe Easy, a breath VOC analysis tool to assess cancer risk.

The page allows users to register interest in Breathe Easy, a breath analysis tool for cancer risk assessment.

The page provides contact details for Dognosis regarding Breathe Easy, clinical partnerships, research, press, and careers, based in Bangalore, Karnataka, India.

Breathe Easy analyses your breath profile, helping your doctor understand your cancer risk. 90.8% sensitivity and 91.3% specificity in a peer-reviewed JCO study.

Dognosis develops a breath-testing platform called **BreathEasy** that uses trained dogs and software to identify cancer risk markers. The system converts canine scent responses into clinical signals for early screening. The company targets broader accessibility beyond traditional hospital-based diagnostics.

Oct 2026yourstory.comNews article

A rescue dog named Chloe in Bengaluru is being trained to detect cancer in human breath samples, assisted by AI technology. The project leverages the dog’s natural olfactory abilities alongside machine learning to improve early cancer diagnosis. This initiative operates on a farm outside India’s tech hub, combining veterinary science and AI for medical research.

Sep 2026France 24News article

Bengaluru startup **Dognosis** develops a breath-test cancer screening method leveraging trained dogs’ olfactory abilities paired with brain-computer interface technology. The solution targets early detection of blood cancers, with plans for a 2027 commercial launch in India. The approach exploits dogs’ superior scent detection, integrated with advanced neural monitoring to identify disease biomarkers.

Jul 2026India TodayNews article

A research team trains dogs like Chloe, a 2-year-old beagle, to detect cancer by analyzing human breath samples. The dogs undergo neurobehavioral monitoring via EEG helmets while interacting with scent stations in a specialized testing lab. The project explores canines’ olfactory capabilities as a diagnostic tool.

Jun 2026Hindustan TimesNews article